Latest property, plant & equipment for IMPL: $7.8M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2023), IMPL shows a PP&E of $7.8M. That compares with $2.8M in the prior-year period — up 181.6% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, IMPL's PP&E is now $7.8M (was $2.8M) — a 181.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Impel Pharmaceuticals is outperforming or lagging.
Tracking IMPL's property, plant & equipment over time shows whether Impel Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $7.8M That compares with $2.8M in the prior-year period — up 181.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this property, plant & equipment page, Stockcircle has Impel Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect PP&E (currently $7.8M) with ownership activity and broader fundamentals.
Impel Pharmaceuticals's PP&E is $7.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.